What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Lung cancer, Oncology, Gefitinib and Surgery.
Erlotinib, Chemotherapy, Hazard ratio, Gemcitabine and Carboplatin are among the areas of Internal medicine where Caicun Zhou concentrates his study.
His work carried out in the field of Lung cancer brings together such families of science as Cancer research, Chemotherapy regimen, Clinical trial, Gastroenterology and Carcinoma.
He interconnects Epidermal growth factor receptor and Pathology in the investigation of issues within Oncology.
Caicun Zhou has researched Surgery in several fields, including Icotinib and Tolerability.
His study in Afatinib is interdisciplinary in nature, drawing from both Rociletinib and Pemetrexed.
His most cited work include:
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study (2762 citations)
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (1436 citations)
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial (1168 citations)
What are the main themes of his work throughout his whole career to date?
Caicun Zhou focuses on Internal medicine, Lung cancer, Oncology, Chemotherapy and Cancer research.
His work is dedicated to discovering how Internal medicine, Surgery are connected with Gastroenterology and other disciplines.
His Lung cancer research is multidisciplinary, incorporating elements of Cancer, Epidermal growth factor receptor and Adenocarcinoma.
His Oncology research includes themes of Gemcitabine and Immunotherapy.
His Chemotherapy research is multidisciplinary, incorporating elements of Clinical endpoint, Adverse effect and Afatinib.
His research in Cancer research focuses on subjects like Immunohistochemistry, which are connected to Tumor-infiltrating lymphocytes.
He most often published in these fields:
- Internal medicine (63.19%)
- Lung cancer (63.38%)
- Oncology (54.08%)
What were the highlights of his more recent work (between 2019-2021)?
- Lung cancer (63.38%)
- Internal medicine (63.19%)
- Oncology (54.08%)
In recent papers he was focusing on the following fields of study:
His main research concerns Lung cancer, Internal medicine, Oncology, Cancer research and Immunotherapy.
His Lung cancer research includes elements of Epidermal growth factor receptor, Tumor microenvironment, CD8, Immune checkpoint inhibitors and Metastasis.
His works in Chemotherapy, non-small cell lung cancer, Incidence, Combination therapy and Stage are all subjects of inquiry into Internal medicine.
His studies in Oncology integrate themes in fields like Adverse effect, Targeted therapy, Clinical trial and Cohort.
His research investigates the link between Cancer research and topics such as Cancer that cross with problems in Immunology and Human leukocyte antigen.
His research integrates issues of Biomarker, Cytotoxic T cell, Radiation therapy and Pneumonitis in his study of Immunotherapy.
Between 2019 and 2021, his most popular works were:
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC (359 citations)
- cGAS-STING, an important pathway in cancer immunotherapy. (16 citations)
- Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study (15 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Caicun Zhou mostly deals with Lung cancer, Cancer research, Internal medicine, Oncology and Immunotherapy.
His studies deal with areas such as Adverse effect, Pediatrics and Adenocarcinoma as well as Lung cancer.
The study incorporates disciplines such as Cancer, Metastasis, Epidermal growth factor receptor, Tumor-infiltrating lymphocytes and Osimertinib in addition to Cancer research.
His Chemotherapy and Carboplatin investigations are all subjects of Internal medicine research.
His work on Non small cell as part of general Oncology research is frequently linked to In patient, thereby connecting diverse disciplines of science.
The various areas that Caicun Zhou examines in his Immunotherapy study include Cytotoxic T cell, CD8 and Ligand.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
